A Phase 3 interventional study of Sildenafil citrate and Sildenafil citrate in Pulmonary Arterial Hypertension, Children, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 41 sites in 17 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2021-02-18.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one is the 2nd largest by enrollment, is one of 2 that started in 2003, is one of 7 in phase 3, and was the 1st registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:
Silvia Ulrich · Sites in Switzerland
Ages 18–80
By country, each count listing its studies:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 8 · Phase 4 6
First in 2002; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 235 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 23 across the 18 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
14 studies in Pulmonary Arterial Hypertension by Viatris Inc.: none open now, none under way, none of them phase 3. Of 9 finished, 8 (89%) have results posted.
Among the 14 studies in Pulmonary Arterial Hypertension by Viatris Inc., this one is the only one that started in 2003, is one of 3 in phase 3, and was the 1st registered.
Viatris Inc.’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 14 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a clinical research study designed to evaluate sildenafil for the treatment of Pulmonary Arterial Hypertension in children, aged 1 to 17 years. The purpose of the study is to assess the efficacy, safety, and pharmacokinetics of 16 weeks of chronic treatment with oral sildenafil given in three different doses, compared to placebo (inactive treatment). Efficacy will be measured by exercise and hemodynamics. Patients who complete this trial may be eligible to take part in an extension study, in which all patients will receive active treatment of sildenafil.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sildenafil citrate
Drug: Sildenafil citrate
Drug: Sildenafil citrate
Drug: Placebo
oral; 20mg, 40mg and 80 mg; 3 times a day(TID)
oral; 10mg, 20mg and 40mg; 3 times a day(TID)
oral; 3 times a day(TID)
oral; 10 mg; 3 times a day(TID)
Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population
Peak VO2 (normalized for body weight) at trough plasma levels assessed by CPX testing (bicycle ergometry)at the end of treatment (Week 16 for those who completed the study). Mean Percent change = \[(week 16 value minus baseline mean)/mean at baseline\]\*100%.
Time frame: Baseline, Week 16
Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Per Protocol Population
Peak VO2 (normalized for body weight) at trough plasma levels assessed by CPX testing (bicycle ergometry)at the end of treatment (Week 16 for those who completed the study). Mean Percent change = \[(week 16 value minus baseline mean)/mean at baseline\]\*100%.
Time frame: Baseline, Week 16
Change From Baseline to Week 16 in Mean Pulmonary Artery Pressure (mPAP)
mPAP, a hemodynamic parameter, was measured using a pressure transducer positioned at the mid-axillary line with the patient in the supine position. Change is observed value at Week 16 minus Baseline value.
Time frame: Baseline, Week 16
Change From Baseline to Week 16 in Pulmonary Vascular Resistance Index (PVRI)
PVRI equals Pulmonary Vascular Resistance (PVR) times Body Surface Area (BSA). Wood unit = 80dyn•s/cm5. Change is observed value at Week 16 minus Baseline value.
Time frame: Baseline, Week 16
Percent Change From Baseline to Week 16 in: Respiratory Exchange Ratio (RER)
RER is the ratio of carbon dioxide produced to oxygen consumed \[VCO2/VO2\]). Percent change is \[(Week 16 value minus Baseline value)/Baseline value\] \* 100%
Time frame: Baseline, Week 16
Percent Change From Baseline to Week 16 in Time to Maximum Volume of Oxygen Consumed (VO2)
Time to maximum VO2 was assessed on the subset of subjects who are developmentally able to perform the exercise test. Percent change is \[(value at Week 16 minus Baseline value)/Baseline value\] \* 100%
Time frame: Baseline, Week 16
Change From Baseline to Week 16 in Pulmonary Vascular Resistance (PVR)
Change calculated as (mean PAP - PCWP)/COpulm in PVR is observed value at Week 16 minus Baseline value.
Time frame: Baseline, Week 16
Change From Baseline to Week 16 in Cardiac Index (CI)
CI is observed value at Week 16 minus Baseline value. Calculated as cardiac output in systemic circulation (COsys) / body surface area (BSA).
Time frame: Baseline, Week 16
Change From Baseline to Week 16 in Right Atrial Pressure (RAP)
RAP was measured using a pressure transducer positioned at the mid-axillary line with the patient in the supine position. Change is observed value at Week 16 minus Baseline value.
Time frame: Baseline, Week 16
Change From Baseline to Week 16 in Child Health Questionnaire Parent Form (CHQ-PF28), Physical Scale
CHQ-PF28: validated generic Quality of Life (QoL) questionnaire for subjects \>= 5 years. Includes 12 domain scores of QoL concepts including physical functioning, social \& school activities, mental health, parent/family concepts. Scores range 0-100: lower scores = lower QoL. Change is observed value at Week 16 minus Baseline value.
Time frame: Baseline, Week 16
Change From Baseline to Week 16 in Child Health Questionnaire Parent Form (CHQ-PF28), Psychosocial Scales
CHQ-PF28: validated generic Quality of Life (QoL) questionnaire for subjects \>= 5 years. Includes 12 domain scores of QoL concepts including physical functioning, social \& school activities, mental health, parent/family concepts. Scores range 0-100: lower scores = lower QoL. Change is observed value at Week 16 minus Baseline value.
Time frame: Baseline, Week 16
Change From Baseline to Week 16 in World Health Organization (WHO) Pulmonary Hypertension (PH) Functional Class
WHO PH functional class definitions adapted from New York Heart Association Criteria for Functional Capacity and Therapeutic Class Definitions. Class I = PH without resulting limitation of physical activity, Class II = PH resulting in slight limitation of physical activity, Class III = PH resulting in marked limitation of physical activity, Class IV = PH with inability to carry out any physical activity without symptoms. Improved by 1 class = Class 4 to 3, Class 3 to 2, Class 2 to 1. Improved by 2 classes = Class 4 to 2, Class 3 to 1. Change is observed value at Week 16 minus Baseline value.
Time frame: Baseline, Week 16
The study was conducted at 32 centers in North, Latin and South America, Europe and Asia.
| Milestone | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Placebo |
|---|---|---|---|---|
| Started | 42 | 55 | 77 | 60 |
| Completed | 40 | 55 | 75 | 58 |
| Not completed | 2 | 0 | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 0 |
Peak VO2 (normalized for body weight) at trough plasma levels assessed by CPX testing (bicycle ergometry)at the end of treatment (Week 16 for those who completed the study). Mean Percent change = \[(week 16 value minus baseline mean)/mean at baseline\]\*100%.
| percent change | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Combined Sildenafil | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population | 6.44 ± 20.16 | 13.40 ± 19.50 | 10.58 ± 15.51 | 10.24 ± 18.39 | 0.53 ± 15.91 |
mPAP, a hemodynamic parameter, was measured using a pressure transducer positioned at the mid-axillary line with the patient in the supine position. Change is observed value at Week 16 minus Baseline value.
| mm Hg | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Combined Sildenafil | Placebo |
|---|---|---|---|---|---|
| Change From Baseline to Week 16 in Mean Pulmonary Artery Pressure (mPAP) | 0.9 ± 12.3 | -3.9 ± 12.0 | -7.4 ± 15.4 | -4.3 ± 13.9 | -0.4 ± 15.9 |
PVRI equals Pulmonary Vascular Resistance (PVR) times Body Surface Area (BSA). Wood unit = 80dyn•s/cm5. Change is observed value at Week 16 minus Baseline value.
| wood units. m2 | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Combined Sildenafil | Placebo |
|---|---|---|---|---|---|
| Change From Baseline to Week 16 in Pulmonary Vascular Resistance Index (PVRI) | 0.1 ± 10.9 | -2.9 ± 11.5 | -5.1 ± 14.7 | -3.2 ± 13.0 | 1.6 ± 9.2 |
RER is the ratio of carbon dioxide produced to oxygen consumed \[VCO2/VO2\]). Percent change is \[(Week 16 value minus Baseline value)/Baseline value\] \* 100%
| percent change | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Combined Sildenafil | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline to Week 16 in: Respiratory Exchange Ratio (RER) | -0.00 ± 0.13 | -0.05 ± 0.12 | -0.02 ± 0.11 | -0.03 ± 0.12 | -0.03 ± 0.11 |
Time to maximum VO2 was assessed on the subset of subjects who are developmentally able to perform the exercise test. Percent change is \[(value at Week 16 minus Baseline value)/Baseline value\] \* 100%
| percent change | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Combined Sildenafil | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline to Week 16 in Time to Maximum Volume of Oxygen Consumed (VO2) | 64.83 ± 103.69 | 64.42 ± 102.70 | 31.33 ± 107.04 | 52.95 ± 104.40 | 8.84 ± 96.09 |
Change calculated as (mean PAP - PCWP)/COpulm in PVR is observed value at Week 16 minus Baseline value.
| wood units | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Combined Sildenafil | Placebo |
|---|---|---|---|---|---|
| Change From Baseline to Week 16 in Pulmonary Vascular Resistance (PVR) | -0.1 ± 10.4 | -3.3 ± 10.5 | -5.2 ± 15.7 | -3.4 ± 13.1 | 0.1 ± 11.8 |
CI is observed value at Week 16 minus Baseline value. Calculated as cardiac output in systemic circulation (COsys) / body surface area (BSA).
| liters/minute/meters squared | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Combined Sildenafil | Placebo |
|---|---|---|---|---|---|
| Change From Baseline to Week 16 in Cardiac Index (CI) | 0.20 ± 1.17 | 0.02 ± 1.44 | 0.24 ± 2.19 | 0.16 ± 1.76 | -0.60 ± 2.12 |
RAP was measured using a pressure transducer positioned at the mid-axillary line with the patient in the supine position. Change is observed value at Week 16 minus Baseline value.
| mm Hg | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Combined Sildenafil | Placebo |
|---|---|---|---|---|---|
| Change From Baseline to Week 16 in Right Atrial Pressure (RAP) | 7.92 ± 2.85 | 8.05 ± 4.42 | 7.75 ± 4.14 | 7.89 ± 3.95 | 8.11 ± 3.61 |
CHQ-PF28: validated generic Quality of Life (QoL) questionnaire for subjects \>= 5 years. Includes 12 domain scores of QoL concepts including physical functioning, social \& school activities, mental health, parent/family concepts. Scores range 0-100: lower scores = lower QoL. Change is observed value at Week 16 minus Baseline value.
| score on scale | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Combined Sildenafil | Placebo |
|---|---|---|---|---|---|
| Change From Baseline to Week 16 in Child Health Questionnaire Parent Form (CHQ-PF28), Physical Scale | 14.0 ± 13.1 | 9.8 ± 11.8 | 5.9 ± 10.5 | 9.4 ± 12.1 | 8.3 ± 12.0 |
CHQ-PF28: validated generic Quality of Life (QoL) questionnaire for subjects \>= 5 years. Includes 12 domain scores of QoL concepts including physical functioning, social \& school activities, mental health, parent/family concepts. Scores range 0-100: lower scores = lower QoL. Change is observed value at Week 16 minus Baseline value.
| score on scale | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Combined Sildenafil | Placebo |
|---|---|---|---|---|---|
| Change From Baseline to Week 16 in Child Health Questionnaire Parent Form (CHQ-PF28), Psychosocial Scales | 5.1 ± 6.9 | 4.1 ± 8.1 | 4.3 ± 10.0 | 4.5 ± 8.6 | 5.6 ± 10.3 |
WHO PH functional class definitions adapted from New York Heart Association Criteria for Functional Capacity and Therapeutic Class Definitions. Class I = PH without resulting limitation of physical activity, Class II = PH resulting in slight limitation of physical activity, Class III = PH resulting in marked limitation of physical activity, Class IV = PH with inability to carry out any physical activity without symptoms. Improved by 1 class = Class 4 to 3, Class 3 to 2, Class 2 to 1. Improved by 2 classes = Class 4 to 2, Class 3 to 1. Change is observed value at Week 16 minus Baseline value.
| units | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Combined Sildenafil | Placebo |
|---|---|---|---|---|---|
| No change | 25 | 24 | 38 | 84 | 31 |
| Improved by 1 class | 6 | 10 | 16 | 32 | 4 |
| Improved by 2 classes | 0 | 0 | 1 | 1 | 0 |
Peak VO2 (normalized for body weight) at trough plasma levels assessed by CPX testing (bicycle ergometry)at the end of treatment (Week 16 for those who completed the study). Mean Percent change = \[(week 16 value minus baseline mean)/mean at baseline\]\*100%.
| percent change | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Combined Sildenafil | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Per Protocol Population | 5.43 ± 20.69 | 15.66 ± 21.48 | 9.34 ± 17.13 | 10.10 ± 19.87 | 2.81 ± 13.17 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sildenafil Low Dose | — | — | — |
| Sildenafil Medium Dose | — | — | — |
| Sildenafil High Dose | — | — | — |
| Combined Sildenafil | — | — | — |
| Placebo | — | — | — |
| Event | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Combined Sildenafil | Placebo |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/42 | 1/55 | 2/77 | 3/174 | 0/60 |
| CyanosisCardiac disorders | 1/42 | 0/55 | 0/77 | 1/174 | 0/60 |
| HaematocheziaGastrointestinal disorders | 1/42 | 0/55 | 0/77 | 1/174 | 0/60 |
| SyncopeNervous system disorders | 1/42 | 0/55 | 0/77 | 1/174 | 0/60 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/42 | 0/55 | 0/77 | 1/174 | 0/60 |
| Upper respiratory tract infectionInfections and infestations | 0/42 | 1/55 | 1/77 | 2/174 | 0/60 |
| DiarrhoeaGastrointestinal disorders | 0/42 | 0/55 | 0/77 | 0/174 | 1/60 |
| Pneumonia bacterialInfections and infestations | 0/42 | 0/55 | 0/77 | 0/174 | 1/60 |
| BradycardiaCardiac disorders | 0/42 | 0/55 | 1/77 | 1/174 | 0/60 |
| Cardiac failure congestiveCardiac disorders | 0/42 | 0/55 | 1/77 | 1/174 | 0/60 |
| Event | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Combined Sildenafil | Placebo |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 5/42 | 6/55 | 12/77 | 23/174 | 8/60 |
| Upper respiratory tract infectionInfections and infestations | 4/42 | 8/55 | 6/77 | 18/174 | 4/60 |
| PyrexiaGeneral disorders | 3/42 | 8/55 | 8/77 | 19/174 | 1/60 |
| VomitingGastrointestinal disorders | 3/42 | 5/55 | 11/77 | 19/174 | 4/60 |
| DiarrhoeaGastrointestinal disorders | 2/42 | 3/55 | 7/77 | 12/174 | 4/60 |
| BronchitisInfections and infestations | 2/42 | 5/55 | 3/77 | 8/174 | 1/60 |
| NauseaGastrointestinal disorders | 0/42 | 4/55 | 4/77 | 8/174 | 0/60 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/42 | 4/55 | 2/77 | 8/174 | 3/60 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/42 | 4/55 | 2/77 | 6/174 | 0/60 |
| NasopharyngitisInfections and infestations | 3/42 | 3/55 | 2/77 | 8/174 | 4/60 |
| Age, Customized(participants) | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Placebo | Total |
|---|---|---|---|---|---|
| 1-4 Years | 0 | 9 | 19 | 7 | 35 |
| 5-12 Years | 25 | 28 | 36 | 37 | 126 |
| 13-17 Years | 17 | 18 | 22 | 16 | 73 |
| >= 18 Years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Female | 25 | 31 | 51 | 38 | 145 |
| Male | 17 | 24 | 26 | 22 | 89 |
The record gives a start of Aug 2003, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pulmonary Arterial Hypertension →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →